Intraarticular gold microparticles using hyaluronic acid as the carrier for hip osteoarthritis. A 2-year follow-up pilot study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 Nov 2024
Historique:
received: 14 04 2024
accepted: 24 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 1 11 2024
Statut: epublish

Résumé

We recently conducted a pilot study in which we discovered that introducing metallic gold microparticles into the knee joint can help reduce pain caused by osteoarthritis for up to two years. Additionally, we identified significant proteomic changes in the synovial fluid and serum within eight weeks of the procedure. In this study, we aimed to evaluate whether there may be a clinical relevant effect of intra-articular injection of gold microparticles on hip osteoarthritis. A cohort of 22 patients, aged ≥ 18 years, with pain ≥ 3 months, and Kellgren-Lawrence OA grade 2-4, were included. Metallic gold 20 mg, 72.000 pieces, 20-40 µ-meter BerlockMicroImplants (BMI) were injected into the hip joint using hyaluronic acid as the carrier. In total, we treated 26 hip joints. The primary outcome was the Western Ontario and McMaster Universities Arthritis Index (WOMAC). WOMAC pain decreased from 11 (2-20 to 3 (0-8), stiffness from 6 (0-8) to 1 (0-4), and activity from 43 (18-68) to 11 (0-27), all P = 0.0001. When adjusting for the minimally relevant differences, the P-values were 0.0015 for WOMAC pain, 0.26 for stiffness, and 0.011 for activity. Combined intraarticular treatment with metallic gold microparticles and hyaluronic acid may improve hip joint pain and function. Joint stiffness did not improve when assessed against the minimal clinically relevant difference. This study suggests a basis for a future placebo-controlled randomized trial of gold microparticles and hyaluronic acid in hip osteoarthritic patients.

Identifiants

pubmed: 39482349
doi: 10.1038/s41598-024-77760-5
pii: 10.1038/s41598-024-77760-5
doi:

Substances chimiques

Hyaluronic Acid 9004-61-9
Gold 7440-57-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26249

Informations de copyright

© 2024. The Author(s).

Références

Murphy, N. J., Eyles, J. P. & Hunter, D. J. Hip osteoarthritis: Etiopathogenesis and implications for management. Adv. Ther. 33(11), 1921–1946. https://doi.org/10.1007/s12325-016-0409-3 (2016).
doi: 10.1007/s12325-016-0409-3 pubmed: 27671326 pmcid: 5083776
Wehling, P., Evans, C., Wehling, J. & Maixner, W. Effectiveness of intra-articular therapies in osteoarthritis: A literature review. Therapeutic Advances in Musculoskeletal Disease 9(8), 183–196. https://doi.org/10.1177/1759720X17712695 (2017).
doi: 10.1177/1759720X17712695 pubmed: 28835778 pmcid: 5557186
Uson, J. et al. EULAR recommendations for intra-articular therapies. Ann. Rheum. Dis. 80(10), 1299–1305. https://doi.org/10.1136/annrheumdis-2021-220266 (2021).
doi: 10.1136/annrheumdis-2021-220266 pubmed: 34035002
Rampal, S. et al. A review of the efficacy of intraarticular hip injection for patients with hip osteoarthritis: To inject or not to inject in hip osteoarthritis?. Joint Diseases and Related Surgery 33(1), 255–262. https://doi.org/10.52312/jdrs.2022.402 (2022).
doi: 10.52312/jdrs.2022.402 pubmed: 35361105 pmcid: 9057559
Choueiri, M., Chevalier, X. & Eymard, F. Intraarticular corticosteroids for hip osteoarthritis: A review. Cartilage 13(1_suppl), 122S-131S. https://doi.org/10.1177/1947603520951634 (2021).
doi: 10.1177/1947603520951634 pubmed: 32815375
Zhong, H. M. et al. Intra-articular steroid injection for patients with hip osteoarthritis: A systematic review and meta-analysis. Biomed. Res. Int. 2020, 6320154. https://doi.org/10.1155/2020/6320154 (2020).
doi: 10.1155/2020/6320154 pubmed: 32185212 pmcid: 7060863
Acuña, A. J., Samuel, L. T., Jeong, S. H., Emara, A. K. & Kamath, A. F. Viscosupplementation for hip osteoarthritis: Does systematic review of patient-reported outcome measures support use?. Journal of Orthopaedics 21, 137–149. https://doi.org/10.1016/j.jor.2020.03.016 (2020).
doi: 10.1016/j.jor.2020.03.016 pubmed: 32255995 pmcid: 7114596
Lim, A., Zhu, J. B. & Khanduja, V. The use of intra-articular platelet-rich plasma as a therapeutic intervention for hip osteoarthritis: A systematic review and meta-analysis. The American Journal of Sports Medicine 51(9), 2487–2497. https://doi.org/10.1177/03635465221095563 (2023).
doi: 10.1177/03635465221095563 pubmed: 35971803
Schmitz, C. et al. Methodological flaws in meta-analyses of clinical studies on the management of knee osteoarthritis with stem cells: A systematic review. Cells 11(6), 965. https://doi.org/10.3390/cells11060965 (2022).
doi: 10.3390/cells11060965 pubmed: 35326416 pmcid: 8946093
Entessari, M. & Oliveira, L. P. Current evidence on mesenchymal stem cells for hip osteoarthritis: A narrative review. Regenerative Medicine 18(9), 749–758. https://doi.org/10.2217/rme-2023-0071 (2023).
doi: 10.2217/rme-2023-0071 pubmed: 37496424
Ferrara, P. E. et al. State of art in intra-articular hip injections of different medications for osteoarthritis: A systematic review. BMC Musculoskeletal Disorders 22(Suppl 2), 997. https://doi.org/10.1186/s12891-021-04866-6 (2021).
doi: 10.1186/s12891-021-04866-6 pubmed: 34844603 pmcid: 8630838
Gazendam, A., Ekhtiari, S., Bozzo, A., Phillips, M. & Bhandari, M. Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: A systematic review and network meta-analysis of randomised controlled trials. British Journal of Sports Medicine 55(5), 256–261. https://doi.org/10.1136/bjsports-2020-102179 (2021).
doi: 10.1136/bjsports-2020-102179 pubmed: 32829298
Rasmussen, S. et al. Gold micro-particles for knee osteoarthritis. European Journal of Pain (London, England) 26(4), 811–824. https://doi.org/10.1002/ejp.1909 (2022).
doi: 10.1002/ejp.1909 pubmed: 35076138
Katz, J. N., Arant, K. R. & Loeser, R. F. Diagnosis and treatment of hip and knee osteoarthritis: A review. JAMA 325(6), 568–578. https://doi.org/10.1001/jama.2020.22171 (2021).
doi: 10.1001/jama.2020.22171 pubmed: 33560326 pmcid: 8225295
Grässel, S. & Muschter, D. Recent advances in the treatment of osteoarthritis. F1000Res https://doi.org/10.12688/f1000research.22115.1 (2020).
doi: 10.12688/f1000research.22115.1 pubmed: 32419923 pmcid: 7199286
Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16(2), 137–162. https://doi.org/10.1016/j.joca.2007.12.013 (2008).
doi: 10.1016/j.joca.2007.12.013 pubmed: 18279766
Danscher, G. & Rasmussen, S. nanoGold and µGold inhibit autoimmune inflammation: A review. Histochemistry and Cell Biology 159(3), 225–232. https://doi.org/10.1007/s00418-023-02182-9 (2023).
doi: 10.1007/s00418-023-02182-9 pubmed: 36864314 pmcid: 10006034
Rasmussen, S., Frederickson, C. & Danscher, G. Inhibition of local inflammation by implanted gold: A narrative review of the history and use of gold. The Journal of Rheumatology 50(5), 704–705. https://doi.org/10.3899/jrheum.221150 (2023).
doi: 10.3899/jrheum.221150 pubmed: 36921973
Märki, N. et al. Safety of intra-articular gold microimplants in horses–A randomized, blinded, controlled experimental study. J. Equine Vet. Sci. 60, 59–66 (2018).
doi: 10.1016/j.jevs.2017.03.005
Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J. & Stitt, L. W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. The Journal of Rheumatology 15(12), 1833–1840 (1988).
pubmed: 3068365
Deckey, D. G. et al. Discordance Abounds in Minimum Clinically Important Differences in THA: A Systematic Review. Clinical Orthopaedics and Related Research 481(4), 702–714. https://doi.org/10.1097/CORR.0000000000002434 (2023).
doi: 10.1097/CORR.0000000000002434 pubmed: 36398323
Kim, M. S. et al. The minimal clinically important difference (MCID) for the WOMAC and factors related to achievement of the MCID after medial opening wedge high tibial osteotomy for knee osteoarthritis. The American Journal of Sports Medicine 49(9), 2406–2415. https://doi.org/10.1177/03635465211016853 (2021).
doi: 10.1177/03635465211016853 pubmed: 34115533
Freynhagen, R., Baron, R., Gockel, U. & Tölle, T. R. painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin. 22, 1911–1920. https://doi.org/10.1185/030079906X132488 (2006).
doi: 10.1185/030079906X132488 pubmed: 17022849
Kamper, S. J., Maher, C. G. & Mackay, G. Global rating of change scales: A review of strengths and weaknesses and considerations for design. The Journal of Manual & Manipulative Therapy 17(3), 163–170. https://doi.org/10.1179/jmt.2009.17.3.163 (2009).
doi: 10.1179/jmt.2009.17.3.163
Lancaster, G. A. & Thabane, L. Guidelines for reporting non-randomised pilot and feasibility studies. Pilot Feasibility Studies 5, 114. https://doi.org/10.1186/s40814-019-0499-1 (2019).
doi: 10.1186/s40814-019-0499-1 pubmed: 31608150 pmcid: 6778655
Schiavi, P. et al. Efficacy and safety of viscosupplementation with hyaluronic acid for hip osteoarthritis: Results from a cross-sectional study with a minimum follow-up of 4 years. Acta Bio-medica Atenei Parmensis 91(14-S), e2020032. https://doi.org/10.23750/abm.v91i14-S.11110 (2020).
doi: 10.23750/abm.v91i14-S.11110 pubmed: 33559627 pmcid: 7944698
GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology 5(9), e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7 (2023).
doi: 10.1016/S2665-9913(23)00163-7
Gibbs, A. J. et al. Recommendations for the management of hip and knee osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthritis and Cartilage 31(10), 1280–1292. https://doi.org/10.1016/j.joca.2023.05.015 (2023).
doi: 10.1016/j.joca.2023.05.015 pubmed: 37394226
Richard, M. J., Driban, J. B. & McAlindon, T. E. Pharmaceutical treatment of osteoarthritis. Osteoarthritis and Cartilage 31(4), 458–466. https://doi.org/10.1016/j.joca.2022.11.005 (2023).
doi: 10.1016/j.joca.2022.11.005 pubmed: 36414224
Batushansky, A. et al. Fundamentals of OA. An initiative of Osteoarthritis and Cartilage. Obesity and metabolic factors in OA. Osteoarthritis and Cartilage 30(4), 501–515. https://doi.org/10.1016/j.joca.2021.06.013 (2022).
doi: 10.1016/j.joca.2021.06.013 pubmed: 34537381
Zhao, K., Ruan, J., Nie, L., Ye, X. & Li, J. Effects of synovial macrophages in osteoarthritis. Frontiers in Immunology 14, 1164137. https://doi.org/10.3389/fimmu.2023.1164137 (2023).
doi: 10.3389/fimmu.2023.1164137 pubmed: 37492583 pmcid: 10364050
Wood, M. J., Miller, R. E. & Malfait, A. M. The genesis of pain in osteoarthritis: Inflammation as a mediator of osteoarthritis pain. Clinics in Geriatric Medicine 38(2), 221–238. https://doi.org/10.1016/j.cger.2021.11.013 (2022).
doi: 10.1016/j.cger.2021.11.013 pubmed: 35410677 pmcid: 9053380
Saltzman, B. M. et al. The therapeutic effect of intra-articular normal saline injections for knee osteoarthritis: A meta-analysis of evidence level 1 studies. The American Journal of Sports Medicine 45(11), 2647–2653. https://doi.org/10.1177/0363546516680607 (2017).
doi: 10.1177/0363546516680607 pubmed: 28027657

Auteurs

Sten Rasmussen (S)

Department of Clinical Medicine, Aalborg University, 249 Selma Lagerløfs Vej, room 11.03.025, DK-9260, Aalborg, Gistrup, Denmark. sten@dcm.aau.dk.
Department of orthopedic surgery, Aalborg University Hospital, Aalborg, Denmark. sten@dcm.aau.dk.

Emilie Skjoldemose (E)

Department of Clinical Medicine, Aalborg University, 249 Selma Lagerløfs Vej, room 11.03.025, DK-9260, Aalborg, Gistrup, Denmark.

Nia Kristine Jørgensen (NK)

Department of Clinical Medicine, Aalborg University, 249 Selma Lagerløfs Vej, room 11.03.025, DK-9260, Aalborg, Gistrup, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH